NCT02269150
Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
At risk: Primary completion moved at least 11 months later.
See at-risk trials from Memorial Sloan Kettering Cancer Center
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 22 versions: 13 with changes below, 9 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 2026 to Oct 2027
- Eligibility criteria expanded, about 4 words
- Publications: details revised at 1 of 1 entry
- Notable Primary and study completion dates: Oct 2025 to Oct 2026v21
- Notable Primary and study completion dates: Oct 2023 to Oct 2025v18
- Notable Primary and study completion dates: Oct 2022 to Oct 2023v17
- Notable Primary and study completion dates: Oct 2021 to Oct 2022v15
Show 7 earlier versionsHide 7 earlier versions
- Notable Primary and study completion dates: Oct 2020 to Oct 2021v14
- Notable Primary and study completion dates: Oct 2019 to Oct 2020v13
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 96 to confirmed 59
- Site details revised
- Notable Primary and study completion dates: Oct 2018 to Oct 2019v11
- Notable Primary completion date: Oct 2017 to Oct 2018
- Eligibility criteria shortened, about 3 words
- Study completion date: Oct 2018
- Study description expanded, about 4 words
- Notable Eligibility criteria expanded, about 21 words
- Study description expanded, about 11 words
- Minor Study description shortened, about 1 wordv5
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Prior to transplant hospitalization, store feces for testing and possible future use. Patients undergo fecal microbiota transplantation with the subject's stored pre-transplantation feces. The post-engraftment Bacteroidetes testing, randomization, and fecal microbiota transplantation procedure should all be performed within a 28-day window, beginning on the first day of engraftment. In the event that engraftment occurs prior to day +7, the 28-day window will start on day +7. Subjects from both arms will be followed for one year after transplantation for development of CDI, which will be treated by their BMT clinicians per the standards of care at MSKCC. Subjects from both arms will also be assessed for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially, if feasible, until one year post randomization and analyzed for microbial diversity and composition.
Subjects from both arms will be followed for one year after randomization for development of CDI, which will be treated by their primary BMT clinician per the standards of care at MSKCC. Subjects from both arms will also be assessed by their BMT clinicians for infections and graft-versus-host disease. During the follow-up period, fecal specimens will be collected serially if feasible until one year post randomization and analyzed for microbial diversity and composition.
Biologicals: fecal microbiota transplantation (FMT)
Other: No fecal microbiota transplantation (FMT), routine management
Sites
1 site in 1 country
- Memorial Sloan Kettering Cancer CenterNew York, New York, United States